John M. Maraganore

7.5k total citations · 2 hit papers
55 papers, 6.0k citations indexed

About

John M. Maraganore is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, John M. Maraganore has authored 55 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 16 papers in Molecular Biology and 15 papers in Genetics. Recurrent topics in John M. Maraganore's work include Blood Coagulation and Thrombosis Mechanisms (20 papers), Venomous Animal Envenomation and Studies (15 papers) and Protease and Inhibitor Mechanisms (11 papers). John M. Maraganore is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (20 papers), Venomous Animal Envenomation and Studies (15 papers) and Protease and Inhibitor Mechanisms (11 papers). John M. Maraganore collaborates with scholars based in United States, Canada and United Kingdom. John M. Maraganore's co-authors include Judy Lieberman, Antonin de Fougerolles, John W. Fenton, Jeffrey I. Weitz, J. Hirsh, Robert L. Heinrikson, David Massel, Monika Hudoba, P Bourdon and K L Ramachandran and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

John M. Maraganore

55 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interfering with disease: a progress report on siRNA-based therapeutics

2007 975 citations Antonin de Fougerolles, John M. Maraganore et al. Nature Reviews Drug Discovery profile →
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

1990 904 citations Jeffrey I. Weitz, John M. Maraganore et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John M. Maraganore United States	32	2.4k	1.7k	1.7k	1.4k	1.3k	55	6.0k
Maurice Petitou France	54	4.8k 2.1×	2.4k 1.4×	1.1k 0.6×	1.7k 1.2×	1.2k 0.9×	182	9.8k
Kenneth J. Clemetson Switzerland	43	1.8k 0.8×	3.8k 2.2×	943 0.6×	797 0.6×	317 0.2×	143	6.7k
Daniel Kirchhofer United States	47	2.4k 1.0×	2.1k 1.2×	405 0.2×	742 0.5×	415 0.3×	116	6.4k
Steven T. Olson United States	50	2.7k 1.2×	4.0k 2.3×	451 0.3×	707 0.5×	368 0.3×	138	7.6k
E. Regoeczi Canada	33	1.2k 0.5×	968 0.6×	310 0.2×	538 0.4×	293 0.2×	140	3.4k
Therese Wiedmer United States	43	2.6k 1.1×	1.9k 1.1×	288 0.2×	632 0.4×	179 0.1×	70	5.8k
Kotoku Kurachi United States	48	4.4k 1.9×	3.1k 1.8×	278 0.2×	473 0.3×	145 0.1×	114	8.6k
Kevin L. Moore United States	37	3.3k 1.4×	1.6k 0.9×	296 0.2×	472 0.3×	191 0.1×	59	8.1k
Gaston Vilaire United States	28	1.3k 0.5×	2.1k 1.2×	366 0.2×	495 0.3×	78 0.1×	46	4.1k
Gary R. Matsueda United States	38	2.5k 1.1×	921 0.5×	435 0.3×	276 0.2×	107 0.1×	116	5.7k

Countries citing papers authored by John M. Maraganore

Since Specialization

Citations

This map shows the geographic impact of John M. Maraganore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Maraganore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Maraganore more than expected).

Fields of papers citing papers by John M. Maraganore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Maraganore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Maraganore. The network helps show where John M. Maraganore may publish in the future.

Co-authorship network of co-authors of John M. Maraganore

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Maraganore. A scholar is included among the top collaborators of John M. Maraganore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Maraganore. John M. Maraganore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maraganore, John M.. (2022). Reflections on Alnylam. Nature Biotechnology. 40(5). 641–650. 18 indexed citations

Rich, Jonathan D., John M. Maraganore, Edward Young, et al.. (2007). Heparin resistance in acute coronary syndromes. Journal of Thrombosis and Thrombolysis. 23(2). 93–100. 12 indexed citations

Fougerolles, Antonin de, et al.. (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nature Reviews Drug Discovery. 6(6). 443–453. 975 indexed citations breakdown →

Kranzhöfer, Roger, et al.. (1999). Systemic Thrombin Inhibition by Hirulog Does Not Alter Medial Smooth Muscle Cell Proliferation and Inflammatory Activation after Vascular Injury in the Rabbit. Cardiovascular Drugs and Therapy. 13(5). 429–434. 11 indexed citations

Ren, Song, John W. Fenton, John M. Maraganore, Aubie Angel, & Garry X. Shen. (1997). Inhibition by Hirulog-1 of Generation of Plasminogen Activator Inhibitor-1 from Vascular Smooth-Muscle Cells Induced by Thrombin. Journal of Cardiovascular Pharmacology. 29(3). 337–342. 6 indexed citations

Cirino, Giuseppe, Carla Cicala, Mariarosaria Bucci, et al.. (1996). Thrombin functions as an inflammatory mediator through activation of its receptor.. The Journal of Experimental Medicine. 183(3). 821–827. 230 indexed citations

Sarembock, Ian J., et al.. (1996). Effectiveness of Hirulog in Reducing Restenosis after Balloon Angioplasty of Atherosclerotic Femoral Arteries in Rabbits. Journal of Vascular Research. 33(4). 308–314. 20 indexed citations

Bittl, John A., John Strony, Jeffrey Brinker, et al.. (1995). Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina. New England Journal of Medicine. 333(12). 764–769. 365 indexed citations

Parry, Marina, John M. Maraganore, & Stuart R. Stone. (1994). Kinetic Mechanism for the Interaction of Hirulog with Thrombin. Biochemistry. 33(49). 14807–14814. 65 indexed citations

10.

Ginsberg, Jeff, Michael T. Nurmohamed, Michael Gent, et al.. (1994). Effects on Thrombin Generation of Single Injections of Hirulog™ in Patients with Calf Vein Thrombosis. Thrombosis and Haemostasis. 72(4). 523–525. 17 indexed citations

11.

Maraganore, John M.. (1994). Hirudin and Hirulog: Advances in antithrombotic therapy. Perspectives in Drug Discovery and Design. 1(3). 461–478. 14 indexed citations

12.

Maraganore, John M.. (1993). Thrombin, Thrombin Inhibitors, and the Arterial Thrombotic Process. Thrombosis and Haemostasis. 70(1). 208–211. 36 indexed citations

13.

Yao, Sheng, J McNatt, H. Vernon Anderson, et al.. (1992). Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion. American Journal of Physiology-Heart and Circulatory Physiology. 262(2). H374–H379. 21 indexed citations

14.

Ofosu, Frederick A., John W. Fenton, John M. Maraganore, et al.. (1992). Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of α-thrombin. Biochemical Journal. 283(3). 893–897. 26 indexed citations

15.

Fenton, John W., German B. Villanueva, Frederick A. Ofosu, & John M. Maraganore. (1991). Thrombin Inhibition by Hirudin: How Hirudin Inhibits Thrombin. Pathophysiology of Haemostasis and Thrombosis. 21(Suppl. 1). 27–31. 58 indexed citations

16.

Kline, Toni, Charles E. Hammond, P Bourdon, & John M. Maraganore. (1991). Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. Biochemical and Biophysical Research Communications. 177(3). 1049–1055. 36 indexed citations

17.

Cadroy, Y, John M. Maraganore, Stephen R. Hanson, & Laurence A. Harker. (1991). Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons.. Proceedings of the National Academy of Sciences. 88(4). 1177–1181. 22 indexed citations

18.

Maraganore, John M., et al.. (1990). Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 29(30). 7095–7101. 380 indexed citations

19.

Chao, B H, Joseph A. Jakubowski, Brian Savage, et al.. (1989). Agkistrodon piscivorus piscivorus platelet aggregation inhibitor: a potent inhibitor of platelet activation.. Proceedings of the National Academy of Sciences. 86(20). 8050–8054. 68 indexed citations

20.

Condrea, Eleonora, et al.. (1987). Comparison of enzymatic and pharmacological activities of lysine-49 and aspartate-49 phospholipases A2 from Agkistrodon piscivorus piscivorus snake venom. Biochemical Pharmacology. 36(10). 1723–1730. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact